Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06194643
Other study ID # 22-01439
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 17, 2023
Est. completion date June 2025

Study information

Verified date December 2023
Source NYU Langone Health
Contact Christina A. Penfield, MD, MPH
Phone 646-754-2700
Email Christina.Penfield@nyulangone.org
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a prospective observational cohort study of platelet phenotype in pregnant patients at high-risk for the development preeclampsia. Blood samples will be collected prior to the initiation of daily aspirin and again in the second trimester to evaluate for platelet changes during pregnancy in patient's as a result of aspirin use and their association with adverse perinatal outcomes.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date June 2025
Est. primary completion date June 2025
Accepts healthy volunteers
Gender Female
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria (Case Group): - Pregnant patients receiving prenatal care prior to 17 weeks at NYU Langone Health- Obstetrics & Gynecology Associates - Age 18-50 years - Singleton viable gestation - Pregnant patients at high risk of preeclampsia: Patients meeting USPSTF recommendation for low-dose aspirin (81 mg/day) prophylaxis for preeclampsia based on clinical risk factors (see below) Inclusion Criteria (Control Group): - Pregnant patients receiving prenatal care prior to 17 weeks at NYU Langone Health- Obstetrics & Gynecology Associates - Age 18-50 years - Singleton viable gestation - Pregnant patients at low risk of preeclampsia: Patients who do not meet USPSTF recommendation for low-dose aspirin (81 mg/day) prophylaxis for preeclampsia based on clinical risk factors. Exclusion Criteria (Case and Control Group): - Allergy to aspirin - Antithrombotic or antiplatelet therapy - Anemia (hemoglobin <10 g/dl) or thrombocytopenia (Platelet count <100,000), or thrombocytosis (Platelet count >600) - Known hemorrhagic diathesis - Planned delivery outside of NYU

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States NYU Langone Health New York New York

Sponsors (1)

Lead Sponsor Collaborator
NYU Langone Health

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Individuals with Overactive Platelets Blood Draw 1 (taken between Weeks 6 and 14)
Primary Number of Individuals with Overactive Platelets Blood Draw 2 (taken between Weeks 24 and 28)
Secondary Incidence of Adverse Pregnancy Outcomes Day 30 Post-Delivery (Up to Month 11)
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05999851 - Multiparametric Assessment of Maternal Vascular Function in the Prediction of Hypertensive Disorders of Pregnancy N/A
Recruiting NCT05687344 - Intensive Postpartum Antihypertensive Treatment Phase 3
Recruiting NCT02020174 - The Preeclampsia Registry
Recruiting NCT06377878 - The Preeclampsia Registry
Recruiting NCT05995106 - mHealth for Hypertensive Disorder of Pregnancy N/A
Completed NCT03309826 - Positive Airway Pressure Treatment of Obstructive Sleep-disordered Breathing in Hypertensive Disorders of Pregnancy N/A
Completed NCT05631067 - Feasibility and Acceptability of Risk Stratification in the Fourth Trimester to Reduce Maternal Morbidity and Mortality N/A
Completed NCT03412552 - Risk Analysis of Intensive Care Mangement on Maternal and Fetal Outcome of Severe Preeclampsia and Eclampsia N/A
Completed NCT03728790 - Remote BP Monitoring in the PP Period N/A
Recruiting NCT05089175 - The Investigation of the Prediction Model and Prevention Strategy of Serious Pregnancy Complications in Hypertensive Disorders of Pregnancy Based on the Chinese Population
Enrolling by invitation NCT05763069 - HOME: Home Monitoring of High-risk Pregnancies
Recruiting NCT06069102 - Optimal Blood Pressure Treatment Thresholds Postpartum Phase 4
Recruiting NCT05659173 - Vitamin D Deficiency With Selected Vitamin D Receptor Gene Polymorphism in Gestational Hypertension
Recruiting NCT06281665 - Treatment With Aspirin After Preeclampsia: TAP Trial Phase 4
Completed NCT05124327 - Remote Monitoring and Follow-up for Postpartum Hypertensive Disorders of Pregnancy N/A
Recruiting NCT06362356 - Microbial Metabolites and Outcomes of Pregnancy Study
Active, not recruiting NCT04580927 - Breastfeeding and Postpartum Cardiovascular Health N/A
Recruiting NCT05655936 - Eliminating Severe Maternal Morbidity With Heart Health Doulas Trial N/A
Enrolling by invitation NCT05835596 - MumCare: Mum's Cardiovascular Health for Life N/A
Completed NCT06019715 - Remote Postpartum Intervention Targeting Movement Behaviors After Hypertensive Disorders of Pregnancy N/A